Reduce reliance on short-acting beta-agonists and oral corticosteroid overuse to improve disease control, reduce exacerbations and long-term adverse effects
Education for both providers and patients on proper inhaler use; recognition of good disease control and measures to reduce acute exacerbations
Improving access to and the appropriate use of spirometry as a tool to accurately diagnose both Asthma and COPD
Proactively focusing on risk mitigation and exacerbation reduction in addition to enhancing our ability to achieve disease control
Drug Companies Step Forward with Voluntary Price Caps on Inhalers
Drug companies Boehringer Ingelheim, AstraZeneca and GSK have announced they are capping out-of-pocket costs for their inhaler products at $35 per month. INHALE applauds all three companies for their decision!…
MEDICATION UPDATE: Inhaled Medication Coverage Changes
BCBSM Update BCBSM approves Flovent ABA for members less than 5 years of age. No prior authorization needed for the 44mcg HFA to bridge coverage due to the Amsmanex inhaler…
General Update Flovent HFA and Flovent Diskus are inhaled corticosteroid medicines used as a controller medicine to treat asthma. Flovent HFA is also used to treat eosinophilic esophagitis (EoE). Glaxo…
INHALE Hosts Inaugural Patient Advisory Board Meeting
The INHALE Patient Advisory Board assembled for its first virtual meeting on November 9th. At this meeting, the group discussed goals of the board, operating norms, meeting cadence, and each advisor’s “why”…
In 2022 INHALE kicked off our collaborative with eleven pilot POs who are helping us shape the way we improve care for asthma and COPD patients across the state of Michigan.
INHALE prepares regular PO and Clinical level newsletters that contain:
Support for the INHALE CQI is provided by Blue Cross Blue Shield of Michigan as part of the BCBSM Value Partnerships program. BCBSM’s Value Partnerships program provides clinical and executive support for all CQI programs.
Although Blue Cross Blue Shield of Michigan and the INHALE CQI work in partnership, the opinions, beliefs, and viewpoints expressed by INHALE CQI do not necessarily reflect the opinions, beliefs, and viewpoints of BCBSM or any of its employees.